Jump Trading Has Trimmed Its Conocophillips (Call) (COP) Holding; Keryx Biopharmaceuticals (KERX) Had 6 Analysts Last Week

June 19, 2017 - By Adrian Mccoy

Jump Trading Llc decreased Conocophillips (Call) (COP) stake by 86.68% reported in 2016Q4 SEC filing. Jump Trading Llc sold 35,800 shares as Conocophillips (Call) (COP)’s stock declined 0.06%. The Jump Trading Llc holds 5,500 shares with $276,000 value, down from 41,300 last quarter. Conocophillips (Call) now has $59.01B valuation. It is 0.00% or $0 reaching $46.53 per share. It is down 9.50% since June 19, 2016 and is uptrending. It has underperformed by 7.20% the S&P500.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 30 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by TH Capital on Monday, August 10. Maxim Group maintained the shares of KERX in report on Thursday, August 6 with “Buy” rating. The firm earned “Underweight” rating on Thursday, August 13 by Morgan Stanley. As per Friday, February 26, the company rating was upgraded by Raymond James. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Market Perform” rating given on Wednesday, September 9 by Raymond James. The firm has “Equal-Weight” rating given on Monday, October 5 by Morgan Stanley. The firm has “Buy” rating given on Tuesday, March 29 by Maxim Group. The company was maintained on Thursday, February 25 by Maxim Group. Cowen & Co downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) on Thursday, July 23 to “Market Perform” rating. Stifel Nicolaus maintained it with “Buy” rating and $9 target in Friday, February 26 report. See Keryx Biopharmaceuticals (NASDAQ:KERX) latest ratings:

11/01/2017 Broker: Citigroup Old Rating: Sell New Rating: Neutral Upgrade

Jump Trading Llc increased Ishares Msci Emerging Markets Etf (Put) (EEM) stake by 9,700 shares to 29,000 valued at $1.02M in 2016Q4. It also upped Vanguard Ftse Emerging Markets Etf (VWO) stake by 16,800 shares and now owns 25,200 shares. Tesla Motors Inc (Call) (NASDAQ:TSLA) was raised too.

Investors sentiment decreased to 0.79 in Q4 2016. Its down 0.01, from 0.8 in 2016Q3. It worsened, as 55 investors sold COP shares while 525 reduced holdings. 103 funds opened positions while 353 raised stakes. 805.56 million shares or 4.06% more from 774.14 million shares in 2016Q3 were reported. Richard Bernstein holds 0.25% or 59,929 shares in its portfolio. Loring Wolcott & Coolidge Fiduciary Ltd Liability Partnership Ma accumulated 80,761 shares or 0.09% of the stock. Savant Capital Ltd Liability Corp reported 6,424 shares stake. Eagleclaw Cap Managment Limited Liability Corporation accumulated 8,545 shares or 0.27% of the stock. Foundation Resources Management invested 4.99% of its portfolio in ConocoPhillips (NYSE:COP). Northwestern Mutual Wealth Mgmt has invested 0.06% in ConocoPhillips (NYSE:COP). First Interstate Savings Bank invested in 0.05% or 5,374 shares. Ssi Invest Management Inc, California-based fund reported 5,762 shares. Somerville Kurt F holds 12,932 shares. Davidson Investment Advsr, Montana-based fund reported 5,795 shares. Norinchukin Bancorporation The invested in 146,660 shares or 0.17% of the stock. Centers Of America Inc has 45,506 shares. Sterneck Cap Llc owns 4,924 shares. 6.74M are owned by International. Texas Yale holds 0.04% of its portfolio in ConocoPhillips (NYSE:COP) for 9,424 shares.

Since May 19, 2017, it had 0 insider buys, and 1 sale for $431,590 activity. 9,091 shares valued at $431,590 were sold by McMorran James D on Friday, May 19.

Analysts await ConocoPhillips (NYSE:COP) to report earnings on July, 27. They expect $0.14 EPS, up 117.72% or $0.93 from last year’s $-0.79 per share. COP’s profit will be $177.55M for 83.09 P/E if the $0.14 EPS becomes a reality. After $-0.02 actual EPS reported by ConocoPhillips for the previous quarter, Wall Street now forecasts -800.00% EPS growth.

Among 22 analysts covering ConocoPhillips (NYSE:COP), 16 have Buy rating, 1 Sell and 5 Hold. Therefore 73% are positive. ConocoPhillips had 55 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, December 15 by Credit Agricole. Barclays Capital maintained ConocoPhillips (NYSE:COP) on Monday, October 12 with “Overweight” rating. Cowen & Co maintained ConocoPhillips (NYSE:COP) rating on Friday, March 31. Cowen & Co has “Outperform” rating and $59 target. Goldman Sachs upgraded ConocoPhillips (NYSE:COP) on Monday, November 28 to “Buy” rating. Citigroup maintained it with “Buy” rating and $65 target in Friday, April 29 report. The firm earned “Neutral” rating on Friday, April 29 by UBS. The stock of ConocoPhillips (NYSE:COP) has “Hold” rating given on Wednesday, September 7 by Jefferies. The stock of ConocoPhillips (NYSE:COP) earned “Neutral” rating by Guggenheim on Wednesday, April 19. The stock of ConocoPhillips (NYSE:COP) has “Buy” rating given on Tuesday, October 20 by Bank of America. RBC Capital Markets maintained ConocoPhillips (NYSE:COP) rating on Monday, October 31. RBC Capital Markets has “Outperform” rating and $53 target.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development of medicines for people with renal disease. The company has market cap of $619.84 million. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. It currently has negative earnings. The Company’s marketed product, Auryxia , which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Investors sentiment increased to 1.22 in Q4 2016. Its up 0.15, from 1.07 in 2016Q3. It improved, as 9 investors sold Keryx Biopharmaceuticals shares while 32 reduced holdings. 19 funds opened positions while 31 raised stakes. 65.62 million shares or 1.53% more from 64.63 million shares in 2016Q3 were reported. Invesco Ltd has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Boston Partners holds 0% or 409,051 shares. Ameriprise Financial owns 0.01% invested in Keryx Biopharmaceuticals (NASDAQ:KERX) for 1.82 million shares. Hudock Group Lc reported 350 shares. Proshare Ltd Llc has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Ubs Asset Mgmt Americas reported 38,214 shares. Northeast Consultants Incorporated holds 46,100 shares. Quantitative Mgmt Ltd Liability Com owns 229,600 shares. Prudential Financial holds 0% or 10,095 shares in its portfolio. Bnp Paribas Arbitrage Sa has 0% invested in Keryx Biopharmaceuticals (NASDAQ:KERX) for 5,637 shares. Geode Mgmt Ltd Limited Liability Company, Massachusetts-based fund reported 750,517 shares. Public Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Abrams Cap Mngmt Ltd Partnership accumulated 5.72M shares. Hsbc Holding Public Limited Company holds 0% or 13,600 shares in its portfolio. Baupost Grp Ltd Liability Ma stated it has 25.79M shares.

About 1.01M shares traded. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since June 19, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.

Since January 5, 2017, it had 0 insider buys, and 15 selling transactions for $284,221 activity. Madison Greg sold $84,853 worth of stock. Adams Brian also sold $3,724 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) shares. Neylan John F. sold $7,697 worth of stock or 1,428 shares. Holmes Scott A also sold $8,603 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) on Monday, May 1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: